5th BEYOND Expo 2025 Creates an Enduring Legacy for Asian Tech Innovation
A record number of exhibitors and unprecedented investor participation defined this year's success. New business matchmaking milestones further elevated BEYOND Expo 2025.
Fund at First Pitch, Innovation Awards, Founder Stage and Founders Club Among Key Initiatives Supporting Entrepreneurs from across Asia.
MACAO, June 9, 2025 /PRNewswire/ — The 5th BEYOND Expo concluded at The Venetian® Macao's Cotai with unprecedented momentum, cementing its role as a cornerstone for Asian tech innovation under the theme 'Empowering Asia, Bridging the World.' From inspiration by startups to wisdom shared by Alibaba Group's Chairman Joe Tsai, tech leaders and visionaries illustrated BEYOND Expo's commitment to supporting tech innovation in Asia. This year's BEYOND Expo attracted a record-breaking 25,000+ visitors, 800+ exhibitors, 300 media representatives, and over 800 investors, including more than 300 family offices and LPs, from over 120 countries — the highest numbers to date.
Covering sectors from AI, Healthcare, Mobility, Property Tech, Clean Energy, Robotics, Fashion Tech, Sports Tech, to Web3, this year marked the largest and most content-rich BEYOND Expo to date. Beyond the breadth of industry focus, BEYOND Expo also deepened its commitment to regional collaboration through a series of forums spotlighting strategic markets such as Southeast Asia, Japan, the Middle East, Latin America, and Europe. This dual emphasis on sector innovation and regional opportunity positioned BEYOND Expo as one of the most prominent and impactful pan-Asian tech gatherings ever held.
BEYOND Expo Co-Founder Dr. LU Gang said, 'This year there has been a tremendous energy around BEYOND Expo, fueled by Asia's rapid rise in frontier technologies and a greater desire for inter-Asian collaboration and cooperation. The products and solutions on display demonstrate just how much AI is transforming so many aspects of our lives, from the food we eat and the clothes we wear to how we interact with each other. Our ecosystem partners, including media, investors, incubators, and suppliers, are driving this momentum and nurturing next-generation technologies.'
BEYOND Expo recognized some of these innovators by presenting 25 Innovation Awards and hosting competitions such as Fund at First Pitch (FAFP), which attracted 150 competitors. JumpStart Media Executive Chairman James Kwan chaired the 2025 FAFP finale, which featured three high profile investors as judges: Artest Management Group (AMG) Chairman, Metta World Peace; Gobi Partners Co-founder and Chairperson, Thomas Tsao, and Lingotto Innovation Managing Partner & Co-Head, Morgan Samet.
BEYOND Expo Co-Founder Jason Ho added, 'The impact of BEYOND Expo 2025 extends beyond the event itself. It has matured into a year-round ecosystem with the BEYOND Global Network and BEYOND Founders Club, initiatives that support the global expansion of Asian tech companies and foster knowledge and resource sharing among entrepreneurs, driving technological advancements to address global challenges.'
Most International Speaker Lineup and Dynamic Stage Experience in BEYOND's History
During the three-day exhibition, BEYOND Expo delivered its most internationally diverse and intellectually stimulating content lineup ever. More than 300 speakers from across the globe, including Greater China, the United States, United Kingdom, Portugal, the Netherlands, Belgium, Brazil, Mexico, UAE, Singapore, Japan, South Korea, Thailand, Malaysia, Indonesia, Vietnam, Pakistan, and beyond, took the stage to share bold ideas and transformative insights.
Seven thematic stages were strategically placed across the expo floor, offering an immersive and accessible experience for all attendees. From visionary keynotes to dynamic roundtables, these sessions spanned global trends and regional collaboration, across topics such as:
Global Vision Summits: The BGlobal Summit, Global Investment Summit, Wealth Summit and Cross-Border E-commerce Ecosystem Forum explored how Asian innovators are scaling globally.
Regional Collaboration Forums: Asia-Europe Tech Forum, Asia-Latam Tech Forum, ORIGIN Southeast Asia Conference, Japan Tech Forum, and the Zayed Sustainability Prize China Forum created rare opportunities for cross-regional partnerships and investment dialogues.
Frontier Tech Spotlights: AI Summit, Web3 + AI Forum, Founders Talk, Transportation & Mobility Summit, Sports Tech Forum, Fashion Tech Forum, International Industrial Design Forum, and Gen Z Founder Forum brought cutting-edge conversations and industry innovation to the forefront.
Women in Tech: The SheTech Summit championed greater representation and leadership for women in the tech ecosystem.
This comprehensive summit program reinforced BEYOND Expo's status as a leading platform for driving innovation, collaboration, and growth in Asia's technology ecosystem.
A Special Focus on Asia's Unicorn Founders
The Opening Ceremony on May 21 convened some of the most influential minds in Asian tech to explore the theme 'What's Next?'. Among the featured speakers were Dr. Jian Wang, President of Zhejiang Lab and Founder of Alibaba Cloud; Carl Pei, Co-founder and CEO of Nothing; Dr. Burt Guo, CEO and Chief Scientist of Sichuan Aerofugia; Yuekai Zhao, Co-founder of Agile Robots SE; and Jingkang Liu, Founder of Insta360. A standout moment was the roundtable with unicorn founders, where these leaders exchanged bold ideas on scaling globally from Asia, a region rapidly emerging as the heartbeat of next-gen innovation.
Building on that momentum, the two-day Founder Talk featured over 30 trailblazing founders driving breakthroughs in AI, robotics, consumer tech, and sustainability. The stage also welcomed over 25 rising stars at the Gen Z Founder Forum and Gen Z Awards Ceremony, where young innovators showcased tech-driven solutions to global challenges. From unicorn visionaries to next-generation disruptors, BEYOND Expo celebrated the full spectrum of entrepreneurial ambition shaping the future of Asia and beyond.
Media Day Previewed BEYOND Expo 2025's Innovation
Held ahead of the main exhibition, the Media Day welcomed Beyond Expo product showcases, Media Day facilitated meaningful exchanges between innovators and the global press, setting the stage for a high-impact expo with worldwide reach.
A showcase for the tech-inspired products of the future
BEYOND Expo showcased over 1,000 high-tech products, targeting daily lifestyle and sustainability solutions. These included biodegradable materials, enhanced earphones and speakers, smart eyewear, healthy food, humanoids, medical devices, robotic pets, sleeping aids, and future mobility solutions. B2B applications included AI-reality-inspired software, medical devices, energy-saving and industrial robots.
Unmatched B2B Engagement and Industry Matchmaking
For the first time, BEYOND Expo hosted multiple on-site business matchmaking sessions over three days, connecting key industry players. Major corporations such as China State Construction International, China Taiping, Sands China, CATL, Tokyu Land Corporation, BMW Group, Sony, Makuake, Mitsubishi Estate, and Panasonic participated, signaling strong demand for real-time, high-value engagement between corporates and innovators. These sessions provided both sides with an efficient platform to identify strategic partners and explore collaborative opportunities.
International Delegations and Buyer Groups Expand Global Reach
This year also saw the participation of numerous international delegations and 'buyer groups,' further amplifying BEYOND Expo's reach. Representatives from Deloitte China, BMW Group, Japanese buyer groups, Western crowdfunding platform executives, and prominent overseas influencers all engaged with exhibitors, many of whom reported valuable feedback and new partnership leads. BEYOND Expo was positioned as a global gateway for companies aiming to scale across Asia and beyond, while spotlighting the region's confidence and capacity in innovation.
Backing the Region's Boldest Innovators
BEYOND Expo further strengthened its commitment to supporting emerging companies with expanded programming tailored for startups. At the heart of Growth Park, a newly launched multi-purpose stage served as a high-impact arena for product unveilings, startup-focused events, and strategic partnership announcements. The Demo Stage, a headline feature of this space, gave rising tech companies the chance to debut their latest innovations in front of a global audience, including investors, media, and industry leaders.
After Hours: Where Innovation Met Entertainment
As day turned to night, BEYOND Expo 2025 transformed into a vibrant celebration where technology and culture seamlessly converged. Each evening featured exclusive events that blended immersive entertainment with meaningful networking opportunities. From Welcome Night and Gala Dinner to dynamic pool parties energized by live DJs, an electrifying performance by Jax Jones, and the breathtaking Cirque Le Soir circus spectacle, BEYOND Expo offered unforgettable experiences that extended the spirit of innovation well beyond the conference halls.
BEYOND Expo 2025 Partners
BEYOND Expo 2025 was made possible with the generous support of Strategic Partners China State Construction International Holdings Limited and China Taiping; Platinum Partners Taobao 88VIP and Macau Pass | MPay; Gold Partner Nam Kwong (Group) Company Limited; Sustainability Partner the Zayed Sustainability Prize; and Venue Partner Sands China Ltd. Additional partners included Asian Family Legacy Foundation, ChainNeXT, Design School of Hunan University, Founders Breakfast, Greenwich Economic Forum, GWA, MAP, INNOBAKER, IESt, Lushan Laboratory, ReGACY Innovation Group, RMI, Sherewires, SIEF, TNGlobal, wteam, and yehyehyeh.
A full list of participating companies can be found here: BEYOND EXPO 2025
About BEYOND Expo
The BEYOND International Technology Innovation Expo (BEYOND Expo) is Asia's leading annual technology event. Serving as a dynamic platform since 2021, BEYOND Expo not only showcases global technological innovations but also provides a unique opportunity to foster innovation upgrades across diverse industries and regions.
BEYOND Expo has attracted participation from Asia's Fortune 500 companies, multinational corporations, unicorn companies, and emerging startups. Through a multifaceted approach involving expos, summits, and various activities, BEYOND Expo has successfully cultivated an innovative ecosystem, propelling collective development in the Asia-Pacific region and the global technology innovation industry. www.beyondexpo.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
3 hours ago
- The Star
Malaysia records approved investments of US$21bil in 1Q
Investment, Trade and Industry Minister Tengku Datuk Seri Zafrul Abdul Aziz.— MUHAMAD SHAHRIL ROSLI/The Star KUALA LUMPUR: Approved investments in Malaysia rose by 3.7% in the first quarter from a year earlier to RM89.8bil (US$21.2bil ), the Malaysian Investment Development Authority said on Wednesday. Foreign investments were RM60.4bil, or two-thirds of the total, and domestic investments accounted for RM29.4bil, the authority said in a statement. "The investment environment in 2025 is expected to remain challenging due to continued geopolitical and macroeconomic headwinds stemming from the U.S.-China trade war," Trade Minister Tengku Datuk Seri Zafrul Abdul Aziz said in the statement. Tengku Zafrul said that while protectionist policies and supply-chain frictions would affect corporate decision-making, he expected Malaysia to attract more investment, given that the broader Asian economy was increasing its share of global GDP. The top three sources of foreign investment in the quarter were Singapore with RM28.3bil, the United States at RM9.9bil and China at RM7.9bil. The services sector attracted RM57.8bil on the approved investments, the authority said. - Reuters
Malaysian Reserve
3 hours ago
- Malaysian Reserve
Kelley Blue Book, Experian Team Up to Bring Buyers Better Vehicle History Reports
Unmatched Trust and Transparency from Detailed Reports to Boost Buyer Confidence and Drive More Conversions ATLANTA and COSTA MESA, Calif., June 10, 2025 /PRNewswire/ — As the market heats up, along with the competition, it has never been more important to make smart car buying choices based on trusted research. As part of its commitment to drive stronger results for our clients, Kelley Blue Book and Autotrader, Cox Automotive brands, today announced they are expanding their strategic relationship with Experian, a global data and technology company, to co-brand its AutoCheck® vehicle history reports on and vehicle listings. Experian's AutoCheck vehicle history reports offered by Kelley Blue Book combine the power of the storied and trusted Kelley Blue Book brand with the detailed insights Experian already delivers to car buyers and sellers for more efficient decision-making. Experian's AutoCheck vehicle history reports will be available on all eligible listings on both Kelley Blue Book and Autotrader, allowing dealerships to provide potential buyers with detailed vehicle history information and inherent trust in their product. Featured on the vehicle history reports, the proprietary AutoCheck Score offers a quick, clear snapshot of a vehicle's predicted reliability, helping buyers and sellers feel confident every step of the way. 'With proprietary auction data and backed by Kelley Blue Book, the No. 1 trusted automotive brand for shoppers planning to buy in the next six months, dealerships can gain the edge they need to better buy and sell inventory,' said Jessica Stafford, senior vice president, consumer solutions, at Cox Automotive. 'Our clients and consumers will have detailed information to make informed car-buying decisions which, given the current market, is more important than ever before. Increased transparency leads to more confident and informed shopper decisions, and ultimately, more leads for dealers.' Dealerships also benefit from more engagement in listings, reporting with an extensive database of automotive records, and easy-to-understand insights to better compare a vehicle to other similar models currently on the market. In fact, free Experian vehicle history reports drive 44% more lead conversions on Autotrader vehicle detail pages than the leading competitor. * 'Researching and comparing vehicle listings is a critical step in the used car buying experience. Nearly every in-market shopper scours every ounce of information available to help them choose the right vehicle,' said Robert Granados, president of Experian Automotive. 'By joining forces with Kelley Blue Book, we're able to put information about a vehicle's history directly into the hands of more consumers. Now, in-market shoppers will have more transparency when buying a vehicle and feel more confident in their choice.' For more information about Experian AutoCheck offered by Kelley Blue Book, contact your Kelley Blue Book or Autotrader sales representative. *Based on internal analysis of vehicle history report leads submitted from Autotrader listings/VDPs from Dec 2024 – May 2025. Individual results may vary. About Kelley Blue Book Founded in 1926, Kelley Blue Book, The Trusted Resource®, is the vehicle valuation and information source trusted and relied upon by both consumers and the automotive industry for nearly a century. As the industry standard for generations, Kelley Blue Book provides transparent, objective information and data-driven, innovative tools for consumers, automotive dealers and manufacturers. Kelley Blue Book publishes millions of market-reflective values weekly on its top-rated website from its famous Blue Book® Trade-In Values to the Kelley Blue Book® Price Advisor tool, which offers a range for what consumers reasonably can expect to pay for a vehicle in their area. editors rate and review hundreds of new vehicles each year to help consumers understand the Best Cars and Best SUVs to meet their needs. Kelley Blue BookSM Instant Cash Offer provides a redeemable trade-in offer to transaction-ready consumers and conveniently connects them to local participating dealers. Kelley Blue Book's Service Advisor provides guidance on how much to pay for service and repairs, allowing consumers to schedule service with local dealers on Kelley Blue Book also provides vehicle values to finance and insurance companies as well as governmental agencies. Kelley Blue Book is a Cox Automotive brand. About Cox AutomotiveCox Automotive is the world's largest automotive services and technology provider. Fueled by the largest breadth of first-party data fed by 2.3 billion online interactions a year, Cox Automotive tailors leading solutions for car shoppers, auto manufacturers, dealers, lenders and fleets. The company has 29,000+ employees on five continents and a portfolio of industry-leading brands that include Autotrader®, Kelley Blue Book®, Manheim®, vAuto®, Dealertrack®, NextGear Capital™, CentralDispatch® and FleetNet America®. Cox Automotive is a subsidiary of Cox Enterprises Inc., a privately owned, Atlanta-based company with $23 billion in annual revenue. Visit or connect via @CoxAutomotive on X, CoxAutoInc on Facebook or Cox-Automotive-Inc on LinkedIn. About ExperianExperian is a global data and technology company, powering opportunities for people and businesses around the world. We help to redefine lending practices, uncover and prevent fraud, simplify healthcare, deliver digital marketing solutions, and gain deeper insights into the automotive market, all using our unique combination of data, analytics and software. We also assist millions of people to realise their financial goals and help them to save time and money. We operate across a range of markets, from financial services to healthcare, automotive, agrifinance, insurance, and many more industry segments. We invest in talented people and new advanced technologies to unlock the power of data and to innovate. A FTSE 100 Index company listed on the London Stock Exchange (EXPN), we have a team of 23,300 people across 32 countries. Our corporate headquarters are in Dublin, Ireland. Learn more at
Malaysian Reserve
4 hours ago
- Malaysian Reserve
Kelun-Biotech Announces Breakthrough Therapy Designation Granted for Sacituzumab Tirumotecan (Sac-TMT) in Combination With Tagitanlimab in China for Certain Types of Non-Small Cell Lung Cancer
CHENGDU, China, June 10, 2025 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the 'Company') today announced that its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) (佳泰莱®) in combination with the PD-L1 monoclonal antibody tagitanlimab (科泰莱®) was granted Breakthrough Therapy Designation by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China for the first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without actionable genomic alterations. Breakthrough Therapy Designation is granted for treatment options that demonstrate significant clinical advantages over currently available treatments and is aimed at expediting the research, development and marketing of innovative treatment options that address clinically urgent medical needs. This designation is based on the efficacy and safety data from the non-squamous cohort of the Phase II OptiTROP-Lung01 study. This marks the fifth Breakthrough Therapy Designation granted to sac-TMT by the NMPA. Sac-TMT has previously received this designation for: Locally advanced or metastatic triple-negative breast cancer (TNBC) in July 2022; EGFR-mutant, locally advanced or metastatic NSCLC after progression on EGFR-TKI therapy in January 2023; Locally advanced or metastatic hormone-receptor positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC) in patients who have previously received at least two lines of systemic chemotherapy in June 2023； First-line treatment of unresectable locally advanced, recurrent or metastatic PD-L1 negative TNBC in March 2024. Results from a Phase 2 OptiTROP-Lung01 study of sac-TMT in combination with tagitanlimab in first-line advanced or metastatic non-squamous NSCLC patients were presented in a poster session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting[1]. Dr. Michael Ge, CEO of Kelun-Biotech said, 'This designation by the NMPA highlights the importance of developing novel therapeutic options for diverse NSCLC subtypes. Sac-TMT in combination with tagitanlimab demonstrated clinically meaningful outcomes in key endpoints for patients with non-squamous NSCLC without actionable genomic alterations as a first-line treatment. We are excited about the therapeutic potential of TROP2 ADC- immunotherapy combinations, and we look forward to working with regulatory authorities in China to bring this combination therapy to patients in need as soon as possible.' [1] Abstract #8529: Lung Cancer – Non-Small Cell Metastatic, ASCO Annual Meeting, 2025 About sac-TMT (佳泰莱®)Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, BC, gastric cancer (GC), gynecological tumors, among others. Sac-TMT is developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells. In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc., Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (includes Mainland China, Hong Kong, Macao, and Taiwan). To date, two indications for sac-TMT have been approved and marketed in China for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting) and EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy. Sac-TMT became the first domestic ADC with global intellectual property rights to be fully approved for marketing. It is also the world's first TROP2 ADC to be approved for marketing in a lung cancer indication. In addition, two new indication applications for sac-TMT for the treatment of adult patients with EGFR-mutant locally advanced or metastatic NSCLC who progressed after treatment with EGFR-TKI therapy and with unresectable locally advanced, metastatic HR+/HER2- BC who have received prior endocrine therapy and other systemic treatments in the advanced or metastatic setting were accepted by the CDE, and were included in the priority review and approval process. As of today, the Company has initiated 8 registrational clinical studies in China. MSD has initiated 14 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or with pembrolizumab2 or other agents for several types of cancer. These studies are sponsored and led by MSD. About Tagitanlimab (科泰莱®)Tagitanlimab is the first PD-L1 mAb globally to receive authorization for the first-line treatment of NPC. Previously, the NMPA has approved the marketing in China of tagitanlimab used in combination with cisplatin and gemcitabine for the first-line treatment of patients with R/M NPC and monotherapy for the treatment of patients with recurrent or metastatic NPC who have failed after prior 2L+ chemotherapy, respectively. About Kelun-BiotechKelun-Biotech ( is a holding subsidiary of Kelun Pharmaceutical ( which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 3 projects have been approved for marketing, 1 project is in the NDA stage, and more than 10 projects are in the clinical stage. The company has established one of the world's leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit Media: klbio_pr@
